Company Deep Dive
Business segments breakdown, earnings transcript analysis, management credibility scoring, competitive landscape, and scenario modelling.
GKOS
HOLDGlaukos Corporation · Healthcare · United States · $9.0B · Avg Vol: $117M/d
COMPANY DESCRIPTION
Glaukos Corporation is an ophthalmic medical technology company dedicated to the development and commercialization of innovative surgical devices and pharmaceutical therapies for the treatment of glaucoma. The company is a pioneer and market leader in Minimally Invasive Glaucoma Surgery (MIGS), leveraging its proprietary iStent technology to establish a new treatment paradigm. Glaukos's competitive strength derives from its first-mover advantage, strong intellectual property, and focus on addressing unmet needs in ophthalmology.
FINANCIAL SUMMARY (USD)
| Year | 2022 | 2023 | 2024 | 2025 | CAGR | TTM | 2026E | 2027E | Fwd CAGR |
|---|---|---|---|---|---|---|---|---|---|
| Revenue | 282.9M | 314.7M | 383.5M | 507.4M | 21.5% | 551.3M | 629.7M | 787.3M | 24.6% |
| EPS | -2.09 | -2.78 | -2.77 | -3.28 | — | -3.29 | — | — | — |
| Shares | 47.8M | 49.1M | 56.4M | 57.5M | +20.4% | 58.7M | — | — | — |
| Debt | 382.5M | 383.7M | 103.4M | 103.9M | -35.2% | 105.9M | — | — | — |
| Equity | 530.0M | 461.8M | 766.9M | 656.2M | 7.4% | — | — | — | — |
| Op CF | -33.1M | -57.8M | -61.3M | -14.8M | — | -8.8M | — | — | — |
| Inv CF | 44.8M | 14.1M | 47.8M | -77.6M | — | — | — | — | — |
| Fin CF | 6.3M | 15.0M | 91.5M | 11.9M | — | — | — | — | — |
SCORE BREAKDOWN
FUNDAMENTALS
SECTOR PEERS
Closest peers in Healthcare, ranked by industry match, size, and score similarity. Cross-listings of GKOS are excluded.
| Ticker | Company | Mkt Cap | StockRank | Signal |
|---|---|---|---|---|
| GKOS | Glaukos Corporation(you) | $9.0B | 35 | HOLD |
| PODD | Insulet Corporation | $11.3B | 47 | HOLD |
| IRTC | iRhythm Holdings, Inc. | $3.6B | 30 | SELL |
| BRKR | Bruker Corporation | $9.2B | 59 | HOLD |
| PEN | Penumbra, Inc. | $12.5B | 54 | HOLD |
| ESTA | Establishment Labs Holdings Inc. | $2.7B | 36 | HOLD |
| TMDX | TransMedics Group, Inc. | $2.5B | 34 | SELL |
| BIO | Bio-Rad Laboratories, Inc. | $8.4B | 62 | HOLD |
| NEOG | Neogen Corporation | $2.0B | 37 | HOLD |
| BFLY | Butterfly Network, Inc. | $1.7B | 34 | SELL |
Peer medians: ROE -25.5% · P/E 27.7x · Gross margin 50.5%